(Total Views: 123)
Posted On: 09/08/2023 3:54:16 PM
Post# of 25102
News Alert: BriaCell (Nasdaq: BCTX) (TSX: BCT) Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
Check out BriaCell's Success In advanced breast cancer: https://globenewswire.com/news-release/2023/0...ancer.html
-Median Survival: 13.5 months (vs. 6.7-9.
-21 of 29 terminal patients treated since 2022 are alive
-No toxicities reported
Check out BriaCell's Success In advanced breast cancer: https://globenewswire.com/news-release/2023/0...ancer.html
-Median Survival: 13.5 months (vs. 6.7-9.
-21 of 29 terminal patients treated since 2022 are alive
-No toxicities reported
(0)
(0)Scroll down for more posts ▼
